Company
Since 1909, Grifols has worked to improve the health and well-being of people around the world.
Innovation
Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.
Sustainability
Grifols' longstanding commitment to people and the planet entails helping society on all fronts.
Investors
Stock Information
Financials
Communications with CNMV and SEC
Corporate Governance
Careers
People are at the heart of our business. We are committed to continued investment in training and development.
Media
Latest news about the company and contact information for journalists and communication professionals.
Partners
At Grifols, we believe in long-term, mutually trusting relationships with our partners.
Connect with us
Showing 501 search results
Grifols celebrates 25th anniversary of its Diagnostic R&D center in Bizkaia, a key driver of its sector leadership
Grifols receives FDA clearance of IND application for Phase 2 trial of immunoglobulin drops for dry eye disease
Grifols delivers strong results across the board, increasing revenues by 7.4%, Adj EBITDA by 14.2% and improving free cash flow by EUR 209m
Grifols partners with IBL International to develop advanced biomarker panels for unique clinical diagnostics platform
Grifols appoints Montse Ribas as Chief Communications and Reputation Officer to strengthen the company's global reputation
Grifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’
Grifols Phase 2/3 trial shows positive impact of immunoglobulin therapy on post-polio patients
Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029
Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow
Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner
Grifols completes enrollment of second cohort in first-in-human Alpha-1 15% subcutaneous option for treating alpha1-antitrypsin deficiency
Infographic results Q1 2025